EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Bogdan Zurawski, Sang-We Kim, Mauricio Mahave, Aurelia Alexandru, Solange Peters, Adam Pluzanski, Reyes Bernabe Caro, Helena Linardou und 15 weitere

Journal of Thoracic Oncology · 2023-08 · 18 (8) · 1055-1069

DOI: 10.1016/j.jtho.2023.04.021 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thoracic Oncology, 2023-08. Verfasst von Martin Reck und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungenClinic Grosshansdorf, Grosshansdorf, Germany. E…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: In CheckMate 227 Part 1, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, regardless of tumor programmed death-ligand 1 (PD-L1) expression. Here, we report post hoc exploratory systemic and intracranial efficacy outcomes and safety by baseline brain metastasis status at 5 years' minimum follow-up. METHODS: Treatment-naive adults with stage IV or recurrent NSCLC without EGFR or ALK alterations, including asymptomatic patients with treated brain metastases, were enrolled. Patients with tumor PD-L1 greater than or equal to 1% were randomized to nivolumab plus ipilimumab, nivolumab, or chemotherapy; patients with tumor PD-L1 less than 1% were randomized to nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy groups. Assessments included OS, systemic and intracranial progression-free survival per blinded independent central review, new brain lesion development, and safety. Brain imaging was performed at baseline (all randomized patients) and approximately every 12 weeks thereafter (patients with baseline brain metastases only). RESULTS: Overall, 202 of 1739 randomized patients had baseline brain metastases (nivolumab plus ipilimumab: 68; chemotherapy: 66). At 61.3 months' minimum follow-up, nivolumab plus ipilimumab prolonged OS versus chemotherapy in patients with baseline brain metastases (hazard ratio = 0.63; 95% confidence interval: 0.43-0.92) and in those without (hazard ratio = 0.76; 95% confidence interval: 0.66-0.87). In patients with baseline brain metastases, 5-year systemic and intracranial progression-free survival rates were higher with nivolumab plus ipilimumab (12% and 16%, respectively) than chemotherapy (0% and 6%). Fewer patients with baseline brain metastases developed new brain lesions with nivolumab plus ipilimumab (4%) versus chemotherapy (20%). No new safety signals were observed. CONCLUSIONS: With all patients off immunotherapy for more than or equal to 3 years, nivolumab plus ipilimumab continued to provide a long-term, durable survival benefit in patients with or without brain metastases. Intracranial efficacy outcomes favored nivolumab plus ipilimumab versus chemotherapy. These results further support nivolumab plus ipilimumab as an efficacious first-line treatment for patients with metastatic NSCLC, regardless of baseline brain metastasis status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungBrain NeoplasmsAdultHumansNivolumabIpilimumabB7-H1 AntigenNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Brain metastasesIntracranial outcomesIpilimumabNSCLCNivolumab

Substanzen

NivolumabIpilimumabB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungenClinic Grosshansdorf, Grosshansdorf, Germany. Electronic address: m.reck@lungenclinic.de.
  • Department of Medical Oncology, Institutul Oncologic Prof. Dr. Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.
  • Department of Hematology/Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Department of Medical Oncology, Sf Nectarie Oncology Center, Craiova, Romania.
  • Chemotherapy Department, Ambulatorium Chemioterapii, Bydgoszcz, Poland.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Förderung

  • Bristol-Myers Squibb Company

Zitieren

APA

Reck, M., Ciuleanu, T. E., Lee, J. S., Schenker, M., Zurawski, B., Kim, S. W., Mahave, M., Alexandru, A., Peters, S., Pluzanski, A., Caro, R. B., Linardou, H., Burgers, J. A., Nishio, M., Martinez-Marti, A., Azuma, K., Axelrod, R., Paz-Ares, L. G., Ramalingam, S. S., …, & Brahmer, J. R. (2023). Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1. Journal of Thoracic Oncology, 18(8), 1055-1069. https://doi.org/10.1016/j.jtho.2023.04.021

Vancouver

Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW, et al. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1. Journal of Thoracic Oncology. 2023;18(8):1055-1069. doi:10.1016/j.jtho.2023.04.021

BibTeX
@article{Reck2023,
  author = {Reck, Martin and Ciuleanu, Tudor-Eliade and Lee, Jong-Seok and Schenker, Michael and Zurawski, Bogdan and Kim, Sang-We and Mahave, Mauricio and Alexandru, Aurelia and Peters, Solange and Pluzanski, Adam and Caro, Reyes Bernabe and Linardou, Helena and Burgers, Jacobus A and Nishio, Makoto and Martinez-Marti, Alex and Azuma, Koichi and Axelrod, Rita and Paz-Ares, Luis G and Ramalingam, Suresh S and Borghaei, Hossein and O'Byrne, Kenneth J and Li, Li and Bushong, Judith and Gupta, Ravi G and Grootendorst, Diederik J and Eccles, Laura J and Brahmer, Julie R},
  title = {Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1},
  journal = {Journal of Thoracic Oncology},
  year = {2023},
  volume = {18},
  number = {8},
  pages = {1055--1069},
  doi = {10.1016/j.jtho.2023.04.021}
}
Kostenlos starten →